Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials

Vatvani AD Kurniawan A Hariyanto TI . Efficacy and safety of fluvoxamine as outpatient treatment for patients with Covid-19: a systematic review and meta-analysis of clinical trials. Ann Pharmacother. Published online March 31, 2023:106002802311622. doi:10.1177/10600280231162243

Kirenga BJ Mugenyi L Sánchez-Rico M , et al Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Mol Psychiatry. Published online March 3, 2023. doi:10.1038/s41380-023-02004-3

Hoertel Sánchez-Rico M Kornhuber J , et al Antidepressant use and its association with 28-day mortality in inpatients with SARS-CoV-2: support for the FIASMA model against COVID-19. J Clin Med. 2022;11(19):5882. doi:10.3390/jcm11195882

Reis G Dos Santos Moreira Silva EA Medeiros Silva DC , et al Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19 : a randomized platform trial. Ann Intern Med. 2023;176(5):667-675. doi:10.7326/M22-3305

Lenze EJ Mattar C Zorumski CF , et al Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292. doi:10.1001/jama.2020.22760

Hoertel N. Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19? JAMA Netw Open. 2021;4(11):e2136510. doi:10.1001/jamanetworkopen.2021.36510

Deng J Rayner D Ramaraju HB , et al Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;29:578-586. doi:10.1016/j.cmi.2023.01.010

Fritz BA Hoertel N Lenze EJ Jalali F Reiersen AM. Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. Transl Psychiatry. 2022;12(1):341. doi:10.1038/s41398-022-02109-3

Zeng G Liu J Liu S. Re: “efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis” by Deng et al. Clin Microbiol Infect. 2023;29(6):814. doi:10.1016/j.cmi.2023.01.024

Hoertel N Boulware DR Sánchez-Rico M Burgun A Limosin F. Prevalence of contraindications to nirmatrelvir-ritonavir among hospitalized patients with COVID-19 at risk for progression to severe disease. JAMA Netw Open. 2022;5(11):e2242140. doi:10.1001/jamanetworkopen.2022.42140